Mark Socinski, MD
Enriched profileExecutive Medical Director, AdventHealth Cancer Institute · AdventHealth Cancer Institute
Mark Socinski is Executive Medical Director, AdventHealth Cancer Institute at AdventHealth Cancer Institute. OpenAlex indexes 783 publications with 36,990 citations (h-index 84); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Mark Socinski, MD, is Executive Medical Director, AdventHealth Cancer Institute. The public record shows 783 publications with 36,990 citations (h-index 84), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 51 companies.
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Lung Cancer Treatments and Mutations
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 51 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 335.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Sponsor: Nuvation Bio Inc.
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Sponsor: Nuvalent Inc.
Industry payments
Updated 14 Oct 2026
51 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202531 payments$59,975openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202532 payments$54,050openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year202548 payments$46,254openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
33.7%Phenothiazine17.1%Prochlorperazine Maleate100%Part D≥21 patientsBenzodiazepine10.4%Lorazepam100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
30.1%Serotonin-3 Receptor Antagonist14.5%Ondansetron Hcl100%Part D≥20 patientsCorticosteroid9.3%Prednisone100%Part D<11 patients+ 1 more class in this area
Blood & clotting
13%Factor Xa inhibitor13%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
182 congress contributions (2003–2023) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.
ASCO Annual Meeting
ASCO2023Presenting authorPosterTrials in progress - 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
ESMO Congress
ESMO2023Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Nature medicine
Clinical Trial2026 - Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Cancer research communications
Clinical Trial2025 - Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Clinical cancer research
Article2023
Most-cited works
by citation count (OpenAlex)- 01Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCArticle3,776 citations2018
- 02First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerArticle2,584 citations2017
- 03Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsArticle1,757 citations2014
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/asc-communications_worldlungcancerday-podcast-leadershipexcellence-activity-7092224615560724480-PFms
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
onclive.com/authors/mark-a-socinski-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Vermont College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clinician.nejm.org ↗
- Co-Chair Emeritus
Thoracic Malignancies Steering Committee (National Cancer Institute)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →adventhealth.com ↗ - Member
Respiratory Core Committee, Cancer and Leukemia Group B (Alliance)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Member
International Association for the Study of Lung Cancer (IASLC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →adventhealth.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center